GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (OTCPK:LVCLY) » Definitions » Gross Profit

Algorae Pharmaceuticals (Algorae Pharmaceuticals) Gross Profit : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Algorae Pharmaceuticals Gross Profit?

Algorae Pharmaceuticals's gross profit for the six months ended in Dec. 2023 was $0.00 Mil. Algorae Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Algorae Pharmaceuticals's gross profit for the six months ended in Dec. 2023 was $0.00 Mil. Algorae Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Algorae Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

Algorae Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of Algorae Pharmaceuticals was 8.37%. The lowest was 4.90%. And the median was 8.33%.


Algorae Pharmaceuticals Gross Profit Historical Data

The historical data trend for Algorae Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Gross Profit Chart

Algorae Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - - - -

Algorae Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Algorae Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, Algorae Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algorae Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's Gross Profit falls into.



Algorae Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Algorae Pharmaceuticals's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as

Gross Profit (A: Jun. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Algorae Pharmaceuticals's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Algorae Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Algorae Pharmaceuticals  (OTCPK:LVCLY) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Algorae Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Algorae Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Algorae Pharmaceuticals (Algorae Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (Algorae Pharmaceuticals) Headlines